52 related articles for article (PubMed ID: 11279803)
1. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
[TBL] [Abstract][Full Text] [Related]
2. Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion.
Zeng ZC; Tang ZY; Liu KD; Lu JZ; Cai XJ; Xie H
Cancer Immunol Immunother; 1994 Nov; 39(5):332-6. PubMed ID: 7987865
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy.
Rengifo CE; Blanco R; Blanco D; Cedeño M; Frómeta M; Calzado ER
J Biomark; 2013; 2013():627845. PubMed ID: 26317020
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer.
Goodman GE; Hellstrom I; Yelton DE; Murray JL; O'Hara S; Meaker E; Zeigler L; Palazollo P; Nicaise C; Usakewicz J
Cancer Immunol Immunother; 1993; 36(4):267-73. PubMed ID: 8382560
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients.
Wang H; Cao C; Li B; Chen S; Yin J; Shi J; Ye D; Tao Q; Hu P; Epstein A; Ju D
Cancer Immunol Immunother; 2008 May; 57(5):677-84. PubMed ID: 17934732
[TBL] [Abstract][Full Text] [Related]
6. Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies.
Barrett JS; Fisher SJ; Wahl RL
Cancer Immunol Immunother; 1997 May; 44(3):173-8. PubMed ID: 9191877
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.
Wersäll P; Ohlsson I; Biberfeld P; Collins VP; von Krusenstjerna S; Larsson S; Mellstedt H; Boethius J
Cancer Immunol Immunother; 1997 May; 44(3):157-64. PubMed ID: 9191875
[TBL] [Abstract][Full Text] [Related]
8. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.
Han S; Jin G; Wang L; Li M; He C; Guo X; Zhu Q
J Immunol Res; 2014; 2014():268479. PubMed ID: 24818166
[TBL] [Abstract][Full Text] [Related]
9. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
[TBL] [Abstract][Full Text] [Related]
10. Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.
Huh Y; Smith DE; Feng MR
Xenobiotica; 2011 Nov; 41(11):972-87. PubMed ID: 21892879
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
Holt GE; Podack ER; Raez LE
Therapy; 2011 Jan; 8(1):43-54. PubMed ID: 21359153
[TBL] [Abstract][Full Text] [Related]
12. The enlargement of the hormone immune deprivation concept to the blocking of TGFalpha-autocrine loop: EGFR signaling inhibition.
Mulet A; Garrido G; Alvarez A; Menéndez T; Böhmer FD; Pérez R; Fernández LE
Cancer Immunol Immunother; 2006 Jun; 55(6):628-38. PubMed ID: 16328386
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
[TBL] [Abstract][Full Text] [Related]
14. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
15. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
16. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
Goldenberg DM; Juweid M; Dunn RM; Sharkey RM
J Nucl Med Technol; 1997 Mar; 25(1):18-23; quiz 34. PubMed ID: 9239599
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
